{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T16:38:29Z","timestamp":1792600709729,"version":"4.5.0"},"reference-count":64,"publisher":"MyJove Corporation","issue":"216","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JoVE"],"DOI":"10.3791\/67548","type":"journal-article","created":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T19:00:24Z","timestamp":1740164424000},"source":"Crossref","is-referenced-by-count":1,"title":["A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy"],"prefix":"10.3791","author":[{"given":"Liang","family":"Hu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Berahovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiming","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinying","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xianghong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shirley","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haoqi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vita","family":"Golubovskaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijun","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"2098","published-online":{"date-parts":[[2025,2,21]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"561376","DOI":"10.3389\/fonc.2021.561376","type":"journal-article","article-title":"National and subnational incidence, mortality, and years of life lost due to breast cancer in iran: Trends and age-period-cohort analysis since 1990","volume":"11","author":"Ataeinia","year":"2021","unstructured":"Ataeinia, B. et al. National and subnational incidence, mortality, and years of life lost due to breast cancer in iran: Trends and age-period-cohort analysis since 1990. Front Oncol. 11, 561376 (2021).","journal-title":"Front Oncol"},{"key":"ref2","type":"book","volume-title":"Breast cancer conservation therapy","author":"Jordan","year":"2024","unstructured":"Jordan, R. M. Oxenberg, J. Breast cancer conservation therapy. Statpearls. (2024)."},{"issue":"2","key":"ref3","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/0167-8140(89)90025-X","type":"journal-article","article-title":"Combined modality treatment with radiotherapy and chemotherapy","volume":"16","author":"Tannock","year":"1989","unstructured":"Tannock, I. F. Combined modality treatment with radiotherapy and chemotherapy. Radiother Oncol. 16 (2), 83-101 (1989).","journal-title":"Radiother Oncol"},{"issue":"3","key":"ref4","doi-asserted-by":"crossref","first-page":"409","DOI":"10.2217\/fon.11.7","type":"journal-article","article-title":"Chemoradiation therapy in the management of gastrointestinal malignancies","volume":"7","author":"Mcree","year":"2011","unstructured":"Mcree, A. J., Cowherd, S., Wang, A. Z., Goldberg, R. M. Chemoradiation therapy in the management of gastrointestinal malignancies. Future Oncol. 7 (3), 409-426 (2011).","journal-title":"Future Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3389\/fphar.2013.00057","type":"journal-article","article-title":"Systemic cancer therapy: Achievements and challenges that lie ahead","volume":"4","author":"Palumbo","year":"2013","unstructured":"Palumbo, M. O. et al. Systemic cancer therapy: Achievements and challenges that lie ahead. Front Pharmacol. 4, 57 (2013).","journal-title":"Front Pharmacol"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1188049","DOI":"10.3389\/fimmu.2023.1188049","type":"journal-article","article-title":"From bench to bedside: The history and progress of car t cell therapy","volume":"14","author":"Mitra","year":"2023","unstructured":"Mitra, A. et al. From bench to bedside: The history and progress of car t cell therapy. Front Immunol. 14, 1188049 (2023).","journal-title":"Front Immunol"},{"issue":"4","key":"ref7","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.cell.2017.01.016","type":"journal-article","article-title":"The principles of engineering immune cells to treat cancer","volume":"168","author":"Lim","year":"2017","unstructured":"Lim, W. A. June, C. H. The principles of engineering immune cells to treat cancer. Cell. 168 (4), 724-740 (2017).","journal-title":"Cell"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"947648","DOI":"10.3389\/fimmu.2022.947648","type":"journal-article","article-title":"Cytokines as an important player in the context of car-t cell therapy for cancer: Their role in tumor immunomodulation, manufacture, and clinical implications","volume":"13","author":"Silveira","year":"2022","unstructured":"Silveira, C. R. F. et al. Cytokines as an important player in the context of car-t cell therapy for cancer: Their role in tumor immunomodulation, manufacture, and clinical implications. Front Immunol. 13, 947648 (2022).","journal-title":"Front Immunol"},{"issue":"6","key":"ref9","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41551-018-0235-9","type":"journal-article","article-title":"Programming car-t cells to kill cancer","volume":"2","author":"Labanieh","year":"2018","unstructured":"Labanieh, L., Majzner, R. G., Mackall, C. L. Programming car-t cells to kill cancer. Nat Biomed Eng. 2 (6), 377-391 (2018).","journal-title":"Nat Biomed Eng"},{"issue":"4","key":"ref10","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","type":"journal-article","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","unstructured":"Sadelain, M., Brentjens, R., Riviere, I. The basic principles of chimeric antigen receptor design. Cancer Discov. 3 (4), 388-398 (2013).","journal-title":"Cancer Discov"},{"issue":"1","key":"ref11","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","type":"journal-article","article-title":"Teaching an old dog new tricks: Next-generation car t cells","volume":"120","author":"Tokarew","year":"2019","unstructured":"Tokarew, N., Ogonek, J., Endres, S., Von Bergwelt-Baildon, M., Kobold, S. Teaching an old dog new tricks: Next-generation car t cells. Br J Cancer. 120 (1), 26-37 (2019).","journal-title":"Br J Cancer"},{"issue":"20","key":"ref12","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1182\/blood-2010-04-281931","type":"journal-article","article-title":"Eradication of b-lineage cells and regression of lymphoma in a patient treated with autologous t cells genetically engineered to recognize cd19","volume":"116","author":"Kochenderfer","year":"2010","unstructured":"Kochenderfer, J. N. et al. Eradication of b-lineage cells and regression of lymphoma in a patient treated with autologous t cells genetically engineered to recognize cd19. Blood. 116 (20), 4099-4102 (2010).","journal-title":"Blood"},{"issue":"18","key":"ref13","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","type":"journal-article","article-title":"Safety and persistence of adoptively transferred autologous cd19-targeted t cells in patients with relapsed or chemotherapy refractory b-cell leukemias","volume":"118","author":"Brentjens","year":"2011","unstructured":"Brentjens, R. J. et al. Safety and persistence of adoptively transferred autologous cd19-targeted t cells in patients with relapsed or chemotherapy refractory b-cell leukemias. Blood. 118 (18), 4817-4828 (2011).","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1034707","DOI":"10.3389\/fimmu.2022.1034707","type":"journal-article","article-title":"Next generations of car-t cells - new therapeutic opportunities in hematology","volume":"13","author":"Tomasik","year":"2022","unstructured":"Tomasik, J., Jasinski, M., Basak, G. W. Next generations of car-t cells - new therapeutic opportunities in hematology? Front Immunol. 13, 1034707 (2022).","journal-title":"Front Immunol"},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"2114254","DOI":"10.1080\/21645515.2022.2114254","type":"journal-article","article-title":"Current updates on generations, approvals, and clinical trials of car t-cell therapy","volume":"18","author":"Asmamaw Dejenie","year":"2022","unstructured":"Asmamaw Dejenie, T. et al. Current updates on generations, approvals, and clinical trials of car t-cell therapy. Hum Vaccin Immunother. 18 (6), 2114254 (2022).","journal-title":"Hum Vaccin Immunother"},{"key":"ref16","first-page":"100638","type":"journal-article","article-title":"Universal chimeric antigen receptor t cell therapy - the future of cell therapy: A review providing clinical evidence","volume":"33","author":"Sun","year":"2022","unstructured":"Sun, W., Jiang, Z., Jiang, W., Yang, R. Universal chimeric antigen receptor t cell therapy - the future of cell therapy: A review providing clinical evidence. Cancer Treat Res Commun. 33, 100638 (2022).","journal-title":"Cancer Treat Res Commun"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"16015","DOI":"10.1038\/mto.2016.15","type":"journal-article","article-title":"Clinical manufacturing of car t cells: Foundation of a promising therapy","volume":"3","author":"Wang","year":"2016","unstructured":"Wang, X. Riviere, I. Clinical manufacturing of car t cells: Foundation of a promising therapy. Mol Ther Oncolytics. 3, 16015 (2016).","journal-title":"Mol Ther Oncolytics"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.jconrel.2022.11.038","type":"journal-article","article-title":"Polymer- and lipid-based gene delivery technology for car t cell therapy","volume":"353","author":"Pinto","year":"2023","unstructured":"Pinto, I. S., Cordeiro, R. A., Faneca, H. Polymer- and lipid-based gene delivery technology for car t cell therapy. J Control Release. 353, 196-215 (2023).","journal-title":"J Control Release"},{"issue":"11","key":"ref19","doi-asserted-by":"crossref","first-page":"6021","DOI":"10.1172\/JCI138473","type":"journal-article","article-title":"Sleeping beauty-engineered car t cells achieve antileukemic activity without severe toxicities","volume":"130","author":"Magnani","year":"2020","unstructured":"Magnani, C. F. et al. Sleeping beauty-engineered car t cells achieve antileukemic activity without severe toxicities. J Clin Invest. 130 (11), 6021-6033 (2020).","journal-title":"J Clin Invest"},{"issue":"19-20","key":"ref20","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1089\/hum.2021.173","type":"journal-article","article-title":"Choosing the right tool for genetic engineering: Clinical lessons from chimeric antigen receptor-t cells","volume":"32","author":"Irving","year":"2021","unstructured":"Irving, M., Lanitis, E., Migliorini, D., Ivics, Z., Guedan, S. Choosing the right tool for genetic engineering: Clinical lessons from chimeric antigen receptor-t cells. Hum Gene Ther. 32 (19-20), 1044-1058 (2021).","journal-title":"Hum Gene Ther"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"867013","DOI":"10.3389\/fimmu.2022.867013","type":"journal-article","article-title":"The past, present, and future of non-viral car t cells","volume":"13","author":"Moretti","year":"2022","unstructured":"Moretti, A. et al. The past, present, and future of non-viral car t cells. Front Immunol. 13, 867013 (2022).","journal-title":"Front Immunol"},{"issue":"7","key":"ref22","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.jcyt.2024.03.003","type":"journal-article","article-title":"Car-t cell expansion platforms yield distinct t cell differentiation states","volume":"26","author":"Song","year":"2024","unstructured":"Song, H. W. et al. Car-t cell expansion platforms yield distinct t cell differentiation states. Cytotherapy. 26 (7), 757-768 (2024).","journal-title":"Cytotherapy"},{"key":"ref23","doi-asserted-by":"crossref","DOI":"10.12688\/f1000research.12533.1","type":"journal-article","article-title":"Recent advances in bioreactors for cell-based therapies","volume":"7","author":"Stephenson","year":"2018","unstructured":"Stephenson, M. Grayson, W. Recent advances in bioreactors for cell-based therapies. F1000Res. 7, F1000 Faculty Rev-517 (2018).","journal-title":"F1000Res"},{"issue":"16","key":"ref24","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1182\/blood.2021010858","type":"journal-article","article-title":"Investigation of product-derived lymphoma following infusion of piggybac-modified cd19 chimeric antigen receptor t cells","volume":"138","author":"Micklethwaite","year":"2021","unstructured":"Micklethwaite, K. P. et al. Investigation of product-derived lymphoma following infusion of piggybac-modified cd19 chimeric antigen receptor t cells. Blood. 138 (16), 1391-1405 (2021).","journal-title":"Blood"},{"issue":"4","key":"ref25","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1038\/s41591-024-02826-w","type":"journal-article","article-title":"T cell lymphoma and secondary primary malignancy risk after commercial car t cell therapy","volume":"30","author":"Ghilardi","year":"2024","unstructured":"Ghilardi, G. et al. T cell lymphoma and secondary primary malignancy risk after commercial car t cell therapy. Nat Med. 30 (4), 984-989 (2024).","journal-title":"Nat Med"},{"issue":"1","key":"ref26","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1182\/blood.2022015728","type":"journal-article","article-title":"Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified iecs","volume":"140","author":"Steffin","year":"2022","unstructured":"Steffin, D. H. M. et al. Long-term follow-up for the development of subsequent malignancies in patients treated with genetically modified iecs. Blood. 140 (1), 16-24 (2022).","journal-title":"Blood"},{"issue":"32","key":"ref27","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","type":"journal-article","article-title":"Long-term follow-up of anti-cd19 chimeric antigen receptor t-cell therapy","volume":"38","author":"Cappell","year":"2020","unstructured":"Cappell, K. M. et al. Long-term follow-up of anti-cd19 chimeric antigen receptor t-cell therapy. J Clin Oncol. 38 (32), 3805-3815 (2020).","journal-title":"J Clin Oncol"},{"issue":"1","key":"ref28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","type":"journal-article","article-title":"Late events after treatment with cd19-targeted chimeric antigen receptor modified t cells","volume":"26","author":"Cordeiro","year":"2020","unstructured":"Cordeiro, A. et al. Late events after treatment with cd19-targeted chimeric antigen receptor modified t cells. Biol Blood Marrow Transplant. 26 (1), 26-33 (2020).","journal-title":"Biol Blood Marrow Transplant"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1063986","DOI":"10.3389\/fimmu.2022.1063986","type":"journal-article","article-title":"Secondary myeloid neoplasms after cd19 car t therapy in patients with refractory\/relapsed b-cell lymphoma: Case series and review of literature","volume":"13","author":"Zhao","year":"2022","unstructured":"Zhao, A. et al. Secondary myeloid neoplasms after cd19 car t therapy in patients with refractory\/relapsed b-cell lymphoma: Case series and review of literature. Front Immunol. 13, 1063986 (2022).","journal-title":"Front Immunol"},{"issue":"7","key":"ref30","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMp2400209","type":"journal-article","article-title":"Secondary cancers after chimeric antigen receptor t-cell therapy","volume":"390","author":"Verdun","year":"2024","unstructured":"Verdun, N. Marks, P. Secondary cancers after chimeric antigen receptor t-cell therapy. N Engl J Med. 390 (7), 584-586 (2024).","journal-title":"N Engl J Med"},{"issue":"10","key":"ref31","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1038\/s41591-018-0201-9","type":"journal-article","article-title":"Induction of resistance to chimeric antigen receptor t cell therapy by transduction of a single leukemic b cell","volume":"24","author":"Ruella","year":"2018","unstructured":"Ruella, M. et al. Induction of resistance to chimeric antigen receptor t cell therapy by transduction of a single leukemic b cell. Nat Med. 24 (10), 1499-1503 (2018).","journal-title":"Nat Med"},{"issue":"16","key":"ref32","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1182\/blood.2021010813","type":"journal-article","article-title":"Development of car t-cell lymphoma in 2 of 10 patients effectively treated with piggybac-modified cd19 car t cells","volume":"138","author":"Bishop","year":"2021","unstructured":"Bishop, D. C. et al. Development of car t-cell lymphoma in 2 of 10 patients effectively treated with piggybac-modified cd19 car t cells. Blood. 138 (16), 1504-1509 (2021).","journal-title":"Blood"},{"issue":"15","key":"ref33","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1182\/bloodadvances.2019000219","type":"journal-article","article-title":"Clonal expansion of car t cells harboring lentivector integration in the cbl gene following anti-cd22 car t-cell therapy","volume":"3","author":"Shah","year":"2019","unstructured":"Shah, N. N. et al. Clonal expansion of car t cells harboring lentivector integration in the cbl gene following anti-cd22 car t-cell therapy. Blood Adv. 3 (15), 2317-2322 (2019).","journal-title":"Blood Adv"},{"issue":"7709","key":"ref34","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/s41586-018-0178-z","type":"journal-article","article-title":"Disruption of tet2 promotes the therapeutic efficacy of cd19-targeted t cells","volume":"558","author":"Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Disruption of tet2 promotes the therapeutic efficacy of cd19-targeted t cells. Nature. 558 (7709), 307-312 (2018).","journal-title":"Nature"},{"issue":"6","key":"ref35","doi-asserted-by":"crossref","first-page":"1160","DOI":"10.1038\/mt.2013.67","type":"journal-article","article-title":"Mature t-cell lymphomagenesis induced by retroviral insertional activation of janus kinase 1","volume":"21","author":"Heinrich","year":"2013","unstructured":"Heinrich, T. et al. Mature t-cell lymphomagenesis induced by retroviral insertional activation of janus kinase 1. Mol Ther. 21 (6), 1160-1168 (2013).","journal-title":"Mol Ther"},{"issue":"Supplement 1","key":"ref36","doi-asserted-by":"crossref","first-page":"6939","DOI":"10.1182\/blood-2023-178806","type":"journal-article","article-title":"Car+ t-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma","volume":"142","author":"Harrison","year":"2023","unstructured":"Harrison, S. J. et al. Car+ t-cell lymphoma post ciltacabtagene autoleucel therapy for relapsed refractory multiple myeloma. Blood. 142 (Supplement 1), 6939-6939 (2023).","journal-title":"Blood"},{"key":"ref37","volume-title":"Fda requires boxed warning for t cell malignancies following treatment with bcma-directed or cd19-directed autologous chimeric antigen receptor (car) t cell immunotherapies","year":"2024","unstructured":"Administration, F. D. A. Fda requires boxed warning for t cell malignancies following treatment with bcma-directed or cd19-directed autologous chimeric antigen receptor (car) t cell immunotherapies. (2024).","type":"book"},{"issue":"20","key":"ref38","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1182\/blood.2024024166","type":"journal-article","article-title":"Second primary malignancies after commercial car t-cell therapy: Analysis of the fda adverse events reporting system","volume":"143","author":"Elsallab","year":"2024","unstructured":"Elsallab, M. et al. Second primary malignancies after commercial car t-cell therapy: Analysis of the fda adverse events reporting system. Blood. 143 (20), 2099-2105 (2024).","journal-title":"Blood"},{"issue":"2","key":"ref39","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/s41591-023-02767-w","type":"journal-article","article-title":"Unanswered questions following reports of secondary malignancies after car-t cell therapy","volume":"30","author":"Levine","year":"2024","unstructured":"Levine, B. L. et al. Unanswered questions following reports of secondary malignancies after car-t cell therapy. Nat Med. 30 (2), 338-341 (2024).","journal-title":"Nat Med"},{"issue":"1","key":"ref40","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1002\/cncr.21971","type":"journal-article","article-title":"The risk of secondary malignancies over 30 years after the treatment of non-hodgkin lymphoma","volume":"107","author":"Tward","year":"2006","unstructured":"Tward, J. D., Wendland, M. M., Shrieve, D. C., Szabo, A., Gaffney, D. K. The risk of secondary malignancies over 30 years after the treatment of non-hodgkin lymphoma. Cancer. 107 (1), 108-115 (2006).","journal-title":"Cancer"},{"issue":"10","key":"ref41","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41408-019-0237-1","type":"journal-article","article-title":"Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia","volume":"9","author":"Kumar","year":"2019","unstructured":"Kumar, V. et al. Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer J. 9 (10), 75 (2019).","journal-title":"Blood Cancer J"},{"issue":"13","key":"ref42","doi-asserted-by":"crossref","first-page":"4009","DOI":"10.1182\/blood-2006-04-015024","type":"journal-article","article-title":"Modification of antigen-encoding rna increases stability, translational efficacy, and t-cell stimulatory capacity of dendritic cells","volume":"108","author":"Holtkamp","year":"2006","unstructured":"Holtkamp, S. et al. Modification of antigen-encoding rna increases stability, translational efficacy, and t-cell stimulatory capacity of dendritic cells. Blood. 108 (13), 4009-4017 (2006).","journal-title":"Blood"},{"issue":"30","key":"ref43","doi-asserted-by":"crossref","first-page":"E2792","DOI":"10.1073\/pnas.1222534110","type":"journal-article","article-title":"Deciphering the rules by which 5'-utr sequences affect protein expression in yeast","volume":"110","author":"Dvir","year":"2013","unstructured":"Dvir, S. et al. Deciphering the rules by which 5'-utr sequences affect protein expression in yeast. Proc Natl Acad Sci U S A. 110 (30), E2792-2801 (2013).","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"ref44","doi-asserted-by":"crossref","first-page":"572","DOI":"10.2144\/01313rr02","type":"journal-article","article-title":"Vector design for optimal protein expression","volume":"31","author":"Van Der Velden","year":"2001","unstructured":"Van Der Velden, A. W., Voorma, H. O., Thomas, A. A. Vector design for optimal protein expression. Biotechniques. 31 (3), 572, 574, 576-580, passim (2001).","journal-title":"Biotechniques"},{"issue":"Unit 2A","key":"ref45","first-page":"1","type":"journal-article","article-title":"Isolation of mononuclear cells from human cord blood by ficoll-paque density gradient","volume":"Chapter 2","author":"Jaatinen","year":"2007","unstructured":"Jaatinen, T. Laine, J. Isolation of mononuclear cells from human cord blood by ficoll-paque density gradient. Curr Protoc Stem Cell Biol. Chapter 2 Unit 2A 1 (2007).","journal-title":"Curr Protoc Stem Cell Biol"},{"issue":"1","key":"ref46","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.ymthe.2005.07.688","type":"journal-article","article-title":"High-efficiency transfection of primary human and mouse t lymphocytes using rna electroporation","volume":"13","author":"Zhao","year":"2006","unstructured":"Zhao, Y. et al. High-efficiency transfection of primary human and mouse t lymphocytes using rna electroporation. Mol Ther. 13 (1), 151-159 (2006).","journal-title":"Mol Ther"},{"issue":"10","key":"ref47","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1073\/pnas.89.10.4285","type":"journal-article","article-title":"Humanization of an anti-p185her2 antibody for human cancer therapy","volume":"89","author":"Carter","year":"1992","unstructured":"Carter, P. et al. Humanization of an anti-p185her2 antibody for human cancer therapy. Proc Natl Acad Sci U S A. 89 (10), 4285-4289 (1992).","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"7","key":"ref48","doi-asserted-by":"crossref","first-page":"808","DOI":"10.3390\/vaccines12070808","type":"journal-article","article-title":"Her2-cd3-fc bispecific antibody-encoding mrna delivered by lipid nanoparticles suppresses her2-positive tumor growth","volume":"12","author":"Hu","year":"2024","unstructured":"Hu, L. et al. Her2-cd3-fc bispecific antibody-encoding mrna delivered by lipid nanoparticles suppresses her2-positive tumor growth. Vaccines. 12 (7), 808(2024).","journal-title":"Vaccines"},{"issue":"8","key":"ref49","doi-asserted-by":"crossref","first-page":"e126086","DOI":"10.1172\/jci.insight.126086","type":"journal-article","article-title":"DNA-encoded bispecific t cell engagers and antibodies present long-term antitumor activity","volume":"4","author":"Perales-Puchalt","year":"2019","unstructured":"Perales-Puchalt, A. et al. DNA-encoded bispecific t cell engagers and antibodies present long-term antitumor activity. JCI Insight. 4 (8), e126086 (2019).","journal-title":"JCI Insight"},{"issue":"7347","key":"ref50","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature10098","type":"journal-article","article-title":"Global quantification of mammalian gene expression control","volume":"473","author":"Schwanhausser","year":"2011","unstructured":"Schwanhausser, B. et al. Global quantification of mammalian gene expression control. Nature. 473 (7347), 337-342 (2011).","journal-title":"Nature"},{"issue":"1","key":"ref51","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/S0022-2836(05)80019-1","type":"journal-article","article-title":"Features in the 5' non-coding sequences of rabbit alpha and beta-globin mrnas that affect translational efficiency","volume":"235","author":"Kozak","year":"1994","unstructured":"Kozak, M. Features in the 5' non-coding sequences of rabbit alpha and beta-globin mrnas that affect translational efficiency. J Mol Biol. 235 (1), 95-110 (1994).","journal-title":"J Mol Biol"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"e45396","DOI":"10.7554\/eLife.45396","type":"journal-article","article-title":"Translation affects mrna stability in a codon-dependent manner in human cells","volume":"8","author":"Wu","year":"2019","unstructured":"Wu, Q. et al. Translation affects mrna stability in a codon-dependent manner in human cells. Elife. 8, e45396 (2019).","journal-title":"Elife"},{"issue":"2","key":"ref53","doi-asserted-by":"crossref","first-page":"e39","DOI":"10.1002\/cpz1.39","type":"journal-article","article-title":"Cap 1 messenger rna synthesis with co-transcriptional cleancap((r)) analog by in vitro transcription","volume":"1","author":"Henderson","year":"2021","unstructured":"Henderson, J. M. et al. Cap 1 messenger rna synthesis with co-transcriptional cleancap((r)) analog by in vitro transcription. Curr Protoc. 1 (2), e39 (2021).","journal-title":"Curr Protoc"},{"issue":"11","key":"ref54","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1038\/mt.2008.200","type":"journal-article","article-title":"Incorporation of pseudouridine into mrna yields superior nonimmunogenic vector with increased translational capacity and biological stability","volume":"16","author":"Kariko","year":"2008","unstructured":"Kariko, K. et al. Incorporation of pseudouridine into mrna yields superior nonimmunogenic vector with increased translational capacity and biological stability. Mol Ther. 16 (11), 1833-1840 (2008).","journal-title":"Mol Ther"},{"issue":"4","key":"ref55","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1046\/j.1365-201X.2003.01093.x","type":"journal-article","article-title":"Electroporation: Theory and methods, perspectives for drug delivery, gene therapy and research","volume":"177","author":"Gehl","year":"2003","unstructured":"Gehl, J. Electroporation: Theory and methods, perspectives for drug delivery, gene therapy and research. Acta Physiol Scand. 177 (4), 437-447 (2003).","journal-title":"Acta Physiol Scand"},{"issue":"2","key":"ref56","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.bioelechem.2011.06.002","type":"journal-article","article-title":"Nanosecond pulsed electric field induced cytoskeleton, nuclear membrane and telomere damage adversely impact cell survival","volume":"82","author":"Stacey","year":"2011","unstructured":"Stacey, M., Fox, P., Buescher, S., Kolb, J. Nanosecond pulsed electric field induced cytoskeleton, nuclear membrane and telomere damage adversely impact cell survival. Bioelectrochemistry. 82 (2), 131-134 (2011).","journal-title":"Bioelectrochemistry"},{"issue":"3","key":"ref57","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/0167-4781(95)00177-8","type":"journal-article","article-title":"Electroporation-induced damage in mammalian cell DNA","volume":"1264","author":"Meaking","year":"1995","unstructured":"Meaking, W. S., Edgerton, J., Wharton, C. W., Meldrum, R. A. Electroporation-induced damage in mammalian cell DNA. Biochim Biophys Acta. 1264 (3), 357-362 (1995).","journal-title":"Biochim Biophys Acta"},{"issue":"7926","key":"ref58","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1038\/s41586-022-05140-y","type":"journal-article","article-title":"Non-viral, specifically targeted car-t cells achieve high safety and efficacy in b-nhl","volume":"609","author":"Zhang","year":"2022","unstructured":"Zhang, J. et al. Non-viral, specifically targeted car-t cells achieve high safety and efficacy in b-nhl. Nature. 609 (7926), 369-374 (2022).","journal-title":"Nature"},{"issue":"1","key":"ref59","doi-asserted-by":"crossref","first-page":"18160","DOI":"10.1038\/s41598-023-45197-x","type":"journal-article","article-title":"Comparison of two lab-scale protocols for enhanced mrna-based car-t cell generation and functionality","volume":"13","author":"Von Auw","year":"2023","unstructured":"Von Auw, N. et al. Comparison of two lab-scale protocols for enhanced mrna-based car-t cell generation and functionality. Sci Rep. 13 (1), 18160 (2023).","journal-title":"Sci Rep"},{"issue":"2","key":"ref60","first-page":"50","type":"journal-article","article-title":"Insights into cytokine release syndrome and neurotoxicity after cd19-specific car-t cell therapy","volume":"66","author":"Gauthier","year":"2018","unstructured":"Gauthier, J. Turtle, C. J. Insights into cytokine release syndrome and neurotoxicity after cd19-specific car-t cell therapy. Curr Res Transl Med. 66 (2), 50-52 (2018).","journal-title":"Curr Res Transl Med"},{"issue":"1","key":"ref61","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1053\/j.gastro.2018.03.029","type":"journal-article","article-title":"Activity of mesothelin-specific chimeric antigen receptor t cells against pancreatic carcinoma metastases in a phase 1 trial","volume":"155","author":"Beatty","year":"2018","unstructured":"Beatty, G. L. et al. Activity of mesothelin-specific chimeric antigen receptor t cells against pancreatic carcinoma metastases in a phase 1 trial. Gastroenterology. 155 (1), 29-32 (2018).","journal-title":"Gastroenterology"},{"issue":"2","key":"ref62","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1158\/2326-6066.CIR-13-0170","type":"journal-article","article-title":"Mesothelin-specific chimeric antigen receptor mrna-engineered t cells induce anti-tumor activity in solid malignancies","volume":"2","author":"Beatty","year":"2014","unstructured":"Beatty, G. L. et al. Mesothelin-specific chimeric antigen receptor mrna-engineered t cells induce anti-tumor activity in solid malignancies. Cancer Immunol Res. 2 (2), 112-120 (2014).","journal-title":"Cancer Immunol Res"},{"issue":"12","key":"ref63","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","type":"journal-article","article-title":"Safety and efficacy of intratumoral injections of chimeric antigen receptor (car) t cells in metastatic breast cancer","volume":"5","author":"Tchou","year":"2017","unstructured":"Tchou, J. et al. Safety and efficacy of intratumoral injections of chimeric antigen receptor (car) t cells in metastatic breast cancer. Cancer Immunol Res. 5 (12), 1152-1161 (2017).","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"ref64","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.tibtech.2023.08.005","type":"journal-article","article-title":"Chimeric antigen receptor therapy meets mrna technology","volume":"42","author":"Wu","year":"2024","unstructured":"Wu, J., Wu, W., Zhou, B., Li, B. Chimeric antigen receptor therapy meets mrna technology. Trends Biotechnol. 42 (2), 228-240 (2024).","journal-title":"Trends Biotechnol"}],"container-title":["Journal of Visualized Experiments"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/app.jove.com\/t\/67548\/a-nonviral-approach-to-generate-transient-chimeric-antigen-receptor-t","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:40:16Z","timestamp":1792597216000},"score":1,"resource":{"primary":{"URL":"https:\/\/app.jove.com\/t\/67548\/a-nonviral-approach-to-generate-transient-chimeric-antigen-receptor-t"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":64,"journal-issue":{"issue":"216","published-online":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.3791\/67548","relation":{},"ISSN":["1940-087X"],"issn-type":[{"value":"1940-087X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]}}}